… of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized … In
fact, in-hospital mortality rate is significant lower in our cohort of COVID-19 patients treated with …

… With the increasing interest in the use of heparin/LMWH for the treatment of COVID-19,
our study signifies an additional activity of heparin apart from anticoagulation. Having …

… the standard-of-care in the treatment of COVID-19. However, this approach may not be
feasible … COVID-19 patients that received intermediate doses of low molecular weight heparin (…

… In conclusion, in the cohort of patients with Covid-19 treated with high enoxaparin dosages
we observed a 60% reduction of mortality and clinical deterioration and a 50% reduction of …

… novel coronavirus disease (COVID-19). We appreciate the efforts by the authors to present
preliminary data on COVID-19… doses of low-molecular-weight heparin (LMWH) in hospitalized …

… LMWH in patients with COVID-19. This study aims to review and analyze the treatment course
of patients with COVID-19 to investigate the anti-inflammatory effects of heparin and delay …

… thrombotic or thromboembolic disease and COVID-19, endorsed by the International … low
molecular weight heparin (LMWH) or unfractionated heparin (UFH) for hospitalized COVID-19, …

… COVID-19; however, there were insufficient data on the optimal use of the therapeutic dose
for low-molecular-weight heparin (… use of different heparin doses in patients with COVID-19. …

… with CoronaVirus disease-19 (COVID-19). Accordingly, recent data suggested a beneficial
role of low molecular weight heparin (… events in patients with COVID-19. We retrospectively …

… Patients with Corona virus disease 2019 (COVID-19) have … Low molecular weight heparins
(LMWH) are often prescribed … mortality in high-risk patients with COVID-19 [10]. However, …